Promising Early Efficacy and Safety Data for AVA6000 in the Ph 1a Dose Escalation and Ongoing Enrollment in the Ph 1b Expansion Cohorts Announced March 11, 2025
Imfinzi-based regimen demonstrated statistically significant and clinically meaningful EFS improvement in resectable early-stage G/GEJ cancers March 11, 2025
Positive Topline Ph 3 COMPETE Trial Data with n.c.a. 177Lu-edotreotide (ITM-11) in Patients with Grade 1/2 SSTR+ve GEP-NETs Presented March 11, 2025
European Commission Approves Opdivo + Yervoy for the 1L Treatment of Adult Patients with Unresectable or Advanced HCC March 11, 2025
